
News|Articles|December 1, 2005
FDA actions in brief
The injectable antibiotic ertapenem (Invanz, Merck) was approved by FDA to treat moderate-to-severe complicated foot infections due to indicated pathogens in patients who have diabetes without osteomyelitis
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rural health is ailing. Is $50 billion enough to heal it?
2
GLP-1 medications are linked to hair loss in Type 2 diabetes
3
Real-World Safety Experience and Clinical Takeaways from the BE BOLD Trial
4
Recombinant shingles vaccine linked to lower cardiovascular disease risk
5























